Telbivudine Patent Expiration
Telbivudine is Used for treating chronic hepatitis B in adult patients with evidence of viral replication and either elevated serum aminotransferases or active histological disease. It was first introduced by Novartis Pharmaceuticals Corp
Telbivudine Patents
Given below is the list of patents protecting Telbivudine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tyzeka | US7589079 | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
Sep 11, 2023
(Expired) | Novartis |
| Tyzeka | US7858594 | Crystalline and amorphous forms of beta-L-2′-deoxythymidine |
Sep 11, 2023
(Expired) | Novartis |
| Tyzeka | US6569837 | β-L-2′-deoxy pyrimidine nucleosides for the treatment of hepatitis B |
Oct 25, 2020
(Expired) | Novartis |
| Tyzeka | US6395716 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
Aug 10, 2019
(Expired) | Novartis |
| Tyzeka | US6444652 | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
Aug 10, 2019
(Expired) | Novartis |
| Tyzeka | US6566344 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
Aug 10, 2019
(Expired) | Novartis |
| Tyzeka | US7795238 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B |
Aug 10, 2019
(Expired) | Novartis |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Telbivudine's patents.
Latest Legal Activities on Telbivudine's Patents
Given below is the list recent legal activities going on the following patents of Telbivudine.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 17 Oct, 2022 | US7795238 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 15 Jun, 2022 | US7858594 |
| Maintenance Fee Reminder Mailed Critical | 02 May, 2022 | US7795238 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 03 Mar, 2021 | US7589079 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Jun, 2018 | US7858594 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 01 Mar, 2018 | US7795238 |
| Post Issue Communication - Certificate of Correction | 04 Aug, 2011 | US7589079 |
| Post Issue Communication - Certificate of Correction | 18 Jul, 2011 | US7589079 |
| Patent Issue Date Used in PTA Calculation Critical | 28 Dec, 2010 | US7858594 |
| Recordation of Patent Grant Mailed Critical | 28 Dec, 2010 | US7858594 |
Telbivudine's Family Patents
